Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3112-4. doi: 10.1128/AAC.00007-16. Print 2016 May.

Abstract

Placental transfer of the HIV integrase inhibitor raltegravir (RLT) was investigated in term human cotyledons in the maternal-to-fetal (n = 3) and fetal-to-maternal (n = 6) directions. In the maternal-to-fetal direction, the mean ± standard deviation (SD) fetal transfer rate (FTR) was 9.1% ± 1.4%, and the mean ± SD clearance index (IC), i.e., RLT FTR/antipyrine FTR, was 0.28 ± 0.05. In the fetal-to-maternal direction, the mean ± SD CI was 0.31 ± 0.09. Placental transfer of RLT was high in both directions.

MeSH terms

  • Female
  • Fetus / metabolism*
  • Gestational Age
  • HIV Integrase Inhibitors / metabolism*
  • Humans
  • Maternal-Fetal Exchange / physiology
  • Placenta / metabolism*
  • Pregnancy
  • Raltegravir Potassium / metabolism*

Substances

  • HIV Integrase Inhibitors
  • Raltegravir Potassium